|
Active substance |
lumacaftor 100mg/ivacaftor 125mg |
|
Holder |
Parexel International |
|
Status |
Closed |
|
Indication |
Treatment of cystic fibrosis (CF) in patients 6 through 11 years of age who are homozygous for the F508del mutation in the CFTR gene. |
|
Public documents |
|
|
Last update |
06/04/2021 |
Orkambi®
Last updated on 10/09/2024